科技英语新闻:Apple iPad 2 tops U.S. magazine's tablet ratings
SAN FRANCISCO, April 5 (Xinhua) -- Apple Inc.'s iPad 2 has topped the ratings by Consumer Reports, an influential U.S. magazine for product reviews, in the latest tests of the 10 most- promising tablet computers.
According to the ratings released on Tuesday, the Apple iPad 2 with Wi-Fi plus 3G (32G), which is priced at 730 U.S. dollars, topped the ratings, scoring "excellent" in nearly every category.
Besides several models from Apple, other brands tested include Archos, Dell, Motorola, Samsung and Viewsonic. Each tablet was evaluated on 17 criteria, including touch-screen responsiveness, versatility, portability, screen glare and ease of use.
"So far, Apple is leading the tablet market in both quality and price, which is unusual for a company whose products are usually premium priced," Paul Reynolds, electronics editor at Consumer Reports, said in a statement.
The Motorola Xoom, whose price is 800 dollars, stood out as the iPad 2's main rival. It boasts several features that the iPad lacks, including a built-in memory card reader and support for the Flash videos.
The first-generation iPad, priced at 580 dollars, also outscored many of the other models tested but tied with the Motorola Xoom, according to tests by Consumer Reports.
相关文章
- 英语文摘:China urges G7 to cease interfering in its internal affairs
- 英语文摘:HKSAR gov't strongly refutes G7, EU statements on chief executive election
- 英语文摘:Xi's keynote speech at opening ceremony of Boao Forum for Asia Annual Conference 2022 publ
- 英语文摘:Xi attends ceremony marking centenary of Communist Youth League of China
- 英语文摘:Xi talks with Macron over phone
- 英语文摘:External interference in Hong Kong affairs doomed to be self-defeating: Commissioner's off
- 英语文摘:Chinese spokesperson slams Western countries smearing Hong Kong election
- 英语文摘:China calls for equal, balanced global development partnership
- 英语文摘:Xinhua Headlines: A look at younger generation on China's new journey
- 英语文摘:Chinese vice premier reiterates dynamic zero-COVID policy